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Published articles constitute a huge repository of population pharmacokinetic (Pop 
PK) models that can be repurposed to answer dose-related questions. We present a 
Simulation-Informed-Statistically-Aided (SISA) method that can be used to select 
population pharmacokinetic models from literature for repurposing.  
Seven published melphalan PK models, and 1 reference model from FDA NDA 
submission documents were selected. A 30 minute IV infusion of 140 mg/m2 of 
melphalan was simulated using each of the 7 models. The predictive performance of 
each of the models were evaluated using a proposed method called modified standard 
normal deviate (mSND). Five models, M1, M3, M4, M5 and M6 performed well 
predicting the given dose with mSND within 0 -3. A composite dataset was generated 
from these 5 models and used to develop a composite melphalan PK model using First-
order conditional estimation method with interaction (FOCE-I), and the Bayesian 
Hamiltonian Monte Carlo No-U-Turn Sampler (HMC NUTS) estimation methods. Both 
informative and weakly informative priors were tested during the Bayesian estimation. 
For both Bayesian and Non-Bayesian methods, a two compartmental model 
adequately fit the composite data. The parameter estimates and the model predictions 
were in agreement with those from reference model. This confirmed that validity of 
SISA. Again, the findings suggested that literature data can be repurposed to develop 
composite PK models.   
It is hoped that further refinement of this method will provide a more objective 
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1.1 Published articles constitute a huge repository of PK models  
 
Published articles constitute a huge repository of population pharmacokinetic (Pop 
PK) models (Chen et al., 2018, Tsamandouras et al., 2017, Snelder et al., 2019, Xue et 
al., 2011, Nath et al., 2010, Lamba et al., 2010). This provides researchers with a ready 
and inexpensive source of models to answer dose-related questions, before further 
investigations in humans. Selection of Pop PK models from literature could however be 
challenging when you have multiple models to choose from. Direct comparison of the 
model parameters and study design alone do not offer an objective approach for 
selection. There is therefore the need to develop an approach that incorporates the model 
parameters and study design, and apply statistical methods to compare predictions of 
exposure after a single dose.  
In this work, we present a simulation-informed statistically-aided (SISA) method 









1.2 Pharmacokinetic modeling and simulation (M&S) are important tools for drug 
development. 
 
The cost of drug development is huge, about 1 – 3 billion dollars (DiMasi et al., 
2016), and companies are pursuing various strategies to minimize it. Modeling and 
simulation is gaining a wide acceptance in drug development due to its potential to 
reduce the cost of drug development. With a single model, thousands of simulations 
may be performed in silico before actual experiments in animals or man. In addition to 
cost reduction, this approach reduces the number of  participants and experiments to be 
conducted.  
Pharmacokinetic modeling and simulation (M&S) is a powerful tool used by 
clinical pharmacologist to characterize the time course of drugs, and also to predict 
doses. Several clinical questions regarding dose and administration of drugs have been 
answered with simulations and confirmed with actual studies (Aarons et al., 2001).  
Considering the number of PK models in literature, it may be prudent to repurpose 
published PK models than to develop new ones from the scratch. However, the selection 
of the model requires the consideration of multiple factors.  
Firstly, there is the need to compare the subject population from which the PK 
model was developed. This may include gender, race, diseases, etc. Second, one may 
have to compare the design of the pharmacokinetic studies, and lastly the parameters 
from each model. This process is not easy to perform without a well-defined procedures. 
To date, only an empirical approach is used. This approach uses the number of 
citations, relevance of population, or author reputation as criteria for selection of 




might miss the opportunity of selecting the best model for use. A more objective criteria 
that combines study design and PK parameters would greatly enhance PK selection.  
 
1.3 Melphalan pharmacokinetic model in literature 
 
Melphalan was chosen for the purposes of this study because of the availability of 
multiple models in literature. It is an alkylating chemotherapeutic agent, and 
increasingly, it is gaining more acceptance as an important agent for the treatment of 
multiple myeloma (Martino et al., 2013, Kuhne et al., 2008, Mateos et al., 2015).  This 
is due to its myeloablative effect, and availability in both oral (ALKERAN®) and 
intravenous (EVOMELA®) dosage forms.  
 
1.4 Overall goal of this project 
 
The overall objectives of this thesis are to:   
1. Identify population pharmacokinetic models that characterize the disposition of 
melphalan in patients from literature. 
2. Develop a criterion to guide the selection of melphalan models from literature. 
3. Generate composite melphalan pharmacokinetic data from literature through 
simulation. 
4. Develop composite population PK model for melphalan using Bayesian and 








2 REVIEW OF LITERATURE 
 
2.1 PHARMACOKINETIC CONCEPTS 
 
2.1.1 Pharmacokinetics and the disposition of drugs 
 
Pharmacokinetics is a term used in pharmacology to describe the processes of 
absorption (A), distribution (D), metabolism (M) and excretion (E).  After oral or 
subcutaneous administration of a drug, it is absorbed into circulation, and may interact 
with blood components like albumin (Yamasaki et al., 2013). The remainder of the drug 
molecules unbounded to blood components move into different body compartments, 
either passively by diffusion, or actively by transporters.  
The fate of the drug in different body compartments is determined by the 
availability of enzymes (e.g. Cytochrome P450) (Guengerich, 1992), transporters (e.g. 
p-glycoprotein) (Nigam, 2015), and other physiological factors. The enzymes mediate 
the metabolism of the drug into a more soluble form. Both metabolized and parent drugs 
may be excreted from the body via the renal or biliary routes.   
The skin and the gastrointestinal tract are the major sites of drug absorption after 
subcutaneous or oral administration respectively. The liver expresses many enzymes for 
metabolism, making it one of the most important sites for drug metabolism. The bile 




Quantitatively, absorption is described by the absorption rate constant (ka) and the 
bioavailability fraction (F). The absorption rate constant describes the speed of 
absorption, whereas the bioavailability factor describes the extent to which an oral or 
subcutaneous dose is available to systemic circulation relative to intravenous 
administration. Similarly, distribution is described by the volume of distribution 
parameter (V), and elimination by the clearance parameter (Cl ).   
 
2.1.2 Population Pharmacokinetic (Pop PK) models 
 
Population pharmacokinetic models describe the time course of drugs in the body. 
They provide mathematical and statistical description of the absorption (A), distribution 
(D), metabolism (M) and excretion (E) of drugs (Van Der Graaf and Gabrielsson, 2009). 
Pop PK models support the determination of doses for clinical trials, and provide a 
framework for evaluating factors that can influence the ADME processes. Figure 1 
summarizes areas where pharmacokinetic modeling and simulations are commonly used 






Figure 1. Modeling and simulation during drug development. Diagram was obtained 
from (Mould and Upton, 2012). 
 
2.1.3 Pop PK models are non-linear mixed effects compartmental models.  
 
Population pharmacokinetic models are non-linear mixed effect models (Van Der 
Graaf and Gabrielsson, 2009, Aarons et al., 2001). They combine structural (fixed) and 
stochastic (random) models to describe the disposition of drugs. The structure can be 
one (Ren et al., 2019), two (Karatza and Karalis, 2019), or multi compartments (Asaumi 
et al., 2019). The parameters in the structural model are known as fixed-effects, and are 
relevant for the characterization of the absorption (ka and F), distribution (V), and 
elimination (CL or Q).  The stochastic model accounts for the magnitude, and the 
sources of variability in the fixed-effect parameters. The parameters in the stochastic 






The two main types of random effects in population pharmacokinetic model are the 
inter-individual variability (IIV) and the residual error variability. The IIV describes 
differences between individuals which may be attributed to demographic, physiological 
and biochemical differences. The residual error model on the hand accounts for the error 
associated with the collection of the pharmacokinetic samples and potential 
misspecification of the structural PK model.  
 
2.1.4 Schematic presentation of Population pharmacokinetic models  
 
Theoretical or imaginary compartments are used to illustrate pharmacokinetic 
models in a simplified way. The organs and tissues of the body are represented by the 
compartments. The number of compartments in a model depends on the assumptions 
regarding the absorption, distribution and elimination of drug from the body. A 
population pharmacokinetic model may thus be described as one-compartment, two-
compartment or multi-compartment model.  
A one compartmental model assumes that the distribution of drug is limited to only 
a central compartment after administration. This central compartment represents all 
tissues that are able to achieve rapid equilibration with the plasma drug concentration. 
A two compartmental model on the other hand, has an additional peripheral 
compartment that achieves equilibration a little later. Thus, there is a flux of drug 






Figure 2. Schematic representation of one and two-compartmental models after IV and 
oral administration. 
 
2.1.5 Exposure measures 
 
The exposure of a drug describes its concentration in circulation or at the site of 
action over a defined period of time. It is important in pharmacokinetics to determine 
the exposure levels that are relevant to achieve a therapeutic response to a drug. The 
exposure measures commonly used to define the exposure levels are the Ctrough, Cmax, 
Tmax, Tmin, and AUC.  
Ctrough is the minimum quantifiable concentration of a drug measured at time 
Tmin. Cmax, on the other hand, is the maximum concentration of a drug measured at 
time Tmax. The AUC is the concentration under the concentration-time curve calculated 




estimated using non-compartmental analysis (NCA), whereas, the Ctrough, Tmin, 

























2.2 STATISTICAL CONCEPTS 
 
2.2.1 Mathematical presentation of population pharmacokinetic models 
 
The mixed effect model (Drikvandi, 2017) can be represented by the following 
equations: 
y = ft, φ, D +  ε 
φ = φ +  η 
Where 
ε = ~ iid N(0, σ) 
η = ~ N(0,  ω)  
• yi1, …, yij: j repeated measurements on the ith subject, where yij is the plasma 
concentration for subject i measured at time tij.   
• f is a nonlinear function of time which depends on the φ and D. The function 
can be a one, two, or multi-compartmental model. 
• D is the dose of drug administered 
• φi are individual parameters 
• φpop is a vector of population parameters 
• εij is the residual errors associated with plasma concentration measurements, yij  
The nonlinear mixed effect model is the joint probability distribution of (y, φ): 
(,  ;  !) =  " (#$% , ;  !) 





2.2.2 The population pharmacokinetic model of melphalan 
 
The pharmacokinetic profile of melphalan was described by two-compartmental 
model (Figure 2) and expressed by equations below: 
The likelihood of melphalan parameters after a dose of D is infused at time Tinf is 
expressed as:  
L(CL, V1, Q, V2, σ|y1, . . , yn, t1, . . , tn, t, D) =  " L(CL, V1, Q, V2, σ|yi, ti, D)0$%             
=  1√2πσ ∗ e4
%56 ∗7478(9:,;%,<,;,=,>)6                     
 
?(@A, BC, D, BE, F, G) = H ∗ I4JF +  K ∗ I4LF   … … … … … … … … … . . (C)             
 
Where: 
A = 1V1 ∗  k21 −  αβ −  α  
 
B = 1V1 ∗  k21 −  βα −  β  
 
α = 12 ∗ Tksum −  √ksum ∗ ksum − 4 ∗ k21 ∗ k10 Y 






k10 =  CLV1  
k12 =  QV1  
k21 =  QV2  
ksum = k10 + k12 + k21   
 
Hence given the pharmacokinetic parameters of melphalan, the plasma 
concentration (C) at time, t, after an intravenous infusion, D, administered at time, tD, 
over a period of Tinf can be given by the function below: 
If t – tD ≤ Tinf 
@(F) =  GZ[\] ∗ _̂_̀
  HJ ∗ C − I4J∗(F4FG)+ KL ∗ C − I4L∗(F4FG) ab
bc … … … . (Ed)   
 
If not, 
@(F) =  GZ[\] ∗ e
HJ ∗ C − I4J∗Z[\] ∗ I4J∗(F4FG4Z[\])+ KL ∗ C − I4L∗Z[\] ∗ I4L∗(F4FG4Z[\]) f …….(2b) 
 
The function describing the two compartment or biphasic disposition of melphalan 
is presented by the differential equations below: 




dA2dt = A1 ∗ k12 − A2 ∗ k21 … … … … … … … … … … … . . (4)                    
 
2.2.3 The Bayes Rule  
 
For Bayesian approaches,  a prior is required for the computation of a posterior 
distribution in accordance with the Bayes Rule (equation 5). The Bayes rule is the basis 
for inference about the Bayesian population PK parameters (!: CL, V1, Q and V2 ) given 
the data (y) and prior knowledge about model parameters (p((!)). The parameters are 
viewed as random variables with probability distributions that naturally permit the 
characterization of the uncertainty around them.   
j(k|?)  =  j(k) ∗ j(?|k)j(?)   ∝  j(k) ∗ j(?|k) … … … … … … … ….  (m) 
Where: 
• (!|) is the posterior distribution of the parameter given the data; 
• (!) is the prior distribution of the parameters; 
• (|!) is the likelihood function expressed by equation (1). 
 
2.2.4 The Prior distribution  
 
The prior in Bayesian statistics represents our prior beliefs or knowledge about 
a parameter. Priors can be informative, weakly informative or uninformative. 
Informative prior strongly represents information that prevents the data alone from 
influencing the posterior distribution. Uninformative prior on the other hand allows the 




informative priors contain some information about the parameter, but allows the data to 
significantly influence the posterior distribution.  In this work both informative priors, 
parameters from non-Bayesian estimation, and weakly informative priors were used.  
 
Normal priors for the mean of CL, Q, V1, and V2 were used. Cauchy priors were 
used as weakly informative priors for the omega and sigma parameters. The LKJ priors 
were used on the rho parameters. The omega parameters are the variances (diagonals) 
of the variance-covariance matrix of the etas on CL, Q, V1 and V2, whereas the rho 
parameters are the off-diagonal covariance. The sigma parameters are the variances of 
the residual errors. The LKJ is the Cholesky LKJ correlation distribution, and is 
implemented in Stan to model a covariance matrix of a multivariate normal distribution 
(Sorensen and Vasishth, 2015).  
 
2.2.5 The posterior distribution  
 
The posterior distribution as shown in equation (5) summarizes our current state 
of knowledge about a parameter after prior information and data (likelihood) (Gelman, 
2002). Hence with prior information about melphalan PK parameters, and plasma 
concentration data, we are able to generate the marginal distribution for each of the PK 







2.2.6 Posterior predictive distribution  
 
New data (ynew) can be predicted from the posterior distribution using the 
posterior predictive distribution expressed by equation (6). The predicted data is then 
compared with the observed data to determine the accuracy and adequacy of the model.   
(nop|) =  q (nop|!) ∗ (!|)r! … … … … … … … . . (6) 
 
2.2.7 Estimation methods   
 
Estimation methods are used to determine the parameters of a model. In 
frequentist Statistics, the maximum likelihood is one of the commonly used estimation 
methods. It finds a set of parameters that maximizes a likelihood function or minimizes 
the negative log-likelihood of that function. In population pharmacokinetics, the 
calculation of the likelihood is complex since the random effects have to be integrated 
out. To circumvent this difficulty, population pharmacokinetic modeling packages 
implement methods that approximate the true likelihood with another simplified 
function (Mould and Upton, 2013). Some of this approximation techniques include the 
first order-method (FO), and the first-order conditional estimation (FOCE) methods 
(Bauer, 2019). In this work, the non-Bayesian estimation was done in NONMEM using 
the FOCE method. 
 
Bayesian techniques on the other hand are based on Markov Chain Monte Carlo 
(MCMC) simulation, which overcomes the complex integration processes involved in 




therefore do not approximate marginal distribution of the parameters, but gives a sample 
distribution of probable population parameters with mean similar to the maximum 
likelihood values (Bauer, 2019).    
 
2.2.8 The Markov Chain Monte Carlo Simulation (MCMC) 
 
Markov chain simulation or MCMC is based on sequential random sampling of 
parameter values from an approximate distributions, and the corrections applied to those 
draws help to better approximate the posterior distribution (Gelman et al., 2013). Any 
aspect of the posterior distribution may be approximated exactly with a large number of 
Monte Carlo samples (Hoff, 2009). To generate MCMC samples with minimal 
autocorrelation, one needs a large sample draw with the appropriate thinning parameter. 
Samples drawn during the warm-up phase, i.e. before the convergence of the Markov 
chains, are discarded.   
 
2.2.9 Algorithms for MCMC 
 
Algorithms used to implement MCMC include Gibbs sampling (GS), 
Metropolis-Hastings (MH), and the Hamiltonian Monte Carlo (HMC) simulation. Gibbs 
sampling generates draws for the posterior distribution by sampling from the univariate 
full conditional distributions.  
θ%  ~ p(θ% | θ4% , θv4%, … … . θ04%, y ) 
θ  ~ p(θ | θ%  , θv4%, … … . θ04%, y ) 




The Metropolis Hastings algorithm is a general multipurpose MCMC algorithm 
which requires a conditional proposal density which is easy to sample from. The HMC 
algorithm is sensitive to two important parameters, step size (ϵ), and the number of steps 
(L), which when properly tuned, avoids the random walk behavior and sensitivity to 
correlated parameters by taking a series of steps informed by first-order gradient 
information (Neal, 2011, Hoffman and Gelman, 2014). This allows the Markov chain 
to converge to high dimensional target distribution quicker than the Gibbs and 
Metropolis sampling (Hoffman and Gelman, 2014). 
 
The NUTS (No-U-Turn Sampler) is an extension of the HMC algorithm. It 
eliminates the need to tune the number of steps (L). In effect, an empirical NUTS will 
perform as efficiently as a properly tuned HMC without requiring user tuning (Hoffman 
and Gelman, 2014). The NUTS algorithm has been implemented in Stan, and has been 
showing promise to estimating population pharmacokinetic and pharmacodynamic 
models. Examples can be found on the website of Metrum Institute® 
(https://www.metrumrg.com/course/brief-introduction-bayesian-modeling-using-
stan/). In this work, Stan was used for the Bayesian part of the analysis. 
 
2.2.10 Standard Normal Deviate and the Standard Normal Distribution 
 
The standard normal deviate (SND) is derived from the normal distribution .  




The normal distribution is a bell-shaped density curve, symmetrical about its mean 
(µ) with a spread determined by its standard deviation (σ).   
f(x) =  1σ√2π ∗ e4%∗(z4{5 )6  
 
 
The density is called the standard normal distribution when its mean is zero (0) and 
standard deviation is one (1).  
f(x) =  1√2π ∗ e4%∗z6 
 
The standard normal distribution has wide application in science. It has been used 
in reporting analytical results and to guide decision making. For instance, data are 
standardized by subtracting the mean (x) from a reference (µ), and dividing this 
difference by the standard deviation (σ) to construct control charts (Amin, 2001). The 
control charts are then used to guide the acceptance and rejection of analytical or 











3.1 Overview of methodology 
 
The method used in this study is outlined in Figure 3. This included literature 
search for melphalan PK models, simulation of the published PK models, evaluation 
and selection of the PK models, creation of composite melphalan PK dataset, and the 
creation of melphalan composite PK model. 
 
 
Figure 3. Outline for developing a composite pharmacokinetic model. mSND, modified 






3.2 Literature search for melphalan PK models 
 
Six papers describing 7 melphalan Pop PK models were selected for analyses from 
PubMed. These six papers  (Nath et al., 2010, Nath et al., 2007, Mizuno et al., 2018, 
Kuhne et al., 2008, Cho et al., 2018, Mougenot et al., 2004, Cho et al., 2017) are the 
only available published articles that describe melphalan Pop PK. They have been 
summarized in Table 1. The EVOMELA PK reported in the Clinical Pharmacology 
NDA Review packet (Nov, 2015) was used as the reference model. 
 
3.3 Design and Simulations 
 
After selecting the melphalan models, each of them was simulated using their 
respective published pharmacokinetic parameters. The design of the simulation was the 
same for each model with respect to virtual subjects, covariate distribution, dose and 
mode of administration of melphalan. A total of 1000 virtual subjects were simulated. 
Primary covariates, i.e. the covariates that can be measured directly, were simulated 
using the normal distribution: 
 
Primary Covariate ~N (μ, σ) 
 
The mean (u) and standard deviation (sd) used for simulating the covariates are 






Table 1. Summary of demographic and study-related characteristics of literature used 
in this study. 
Model 1 and 2 3 4 5 6 7 
Reference 
C E Nath et 
al 2010 (a/b) 
C E Nath 
et al 2007 
Mizuno 






et al 2004 
Demography             
Number of 
subjects 
100 59 15 84 146 64 
Gender (M/F) 59 / 41 38 /21 11-Apr 53 / 31  90 / 56 22 /42 
Age (yrs) 36-73 0.3 - 18 48-74 37-77 35-72 19-80 
Height (cm) 147-185 92 -137 - 155-188 - 152 - 185 
BSA 1.3-2.6 0.60 - 1 1.5 – 2.51  - 1.37 – 2.21 
Study 
Population 









































            





48-130 - 35 - 102 




HCT 20-45 - - -  - 
CrCL (ml/min) 29-234 - 35 - 164 
11.9 – 
179.8 
 30 - 195 
GFR(ml/min 
1.73m2)  
- 86 - 139 - - - - 
Pharmacokineti
cs 




Total Total Total Total Total 
Dose:   IV IV IV IV IV IV 
Infusion rate 15-95 min 15 min 20 min 20-30 min - 24 hr 












20 to 30 
mg/m2 
Structure of PK 
model 
2CMT  2CMT  2CMT  2CMT  2CMT  2CMT  






Table 2. List of covariates used in the simulations. 
 
 
The derived covariates were calculated from the primary covariates using the 
equations below:  
BMI =  WT(HT0 /100) 
BSA = 0.024265 ∗ HT.v ∗ WT.v 
CrClo =  (140 − AGE) ∗ WT(72 ∗ SCR)  
CrCl =  0.85 ∗ (140 − AGE) ∗ WT(72 ∗ SCR)  
FFM =  9.27 ∗ 1000 ∗ WT6.68 ∗ 1000 + 216 ∗ BMI 
 
FFM =  9.27 ∗ 1000 ∗ WT8.78 ∗ 1000 + 244 ∗ BMI 
 
Variable Unit Mean Standard deviation 
Weight (WT) Kg 70 14 
Age years 60 12 
Height (HT) cm 170 34 
Serum Creatinine (SCR) mg/dl 1.1 0.22 




The proportion of female to male virtual subjects was 2:3. Using a 30 minutes IV 
infusion of 140 mg/m2, each model was simulated using the respective published 
pharmacokinetic parameters.  
 
3.3.1 Calculation of Exposure measures 
 
The exposure measures, AUCinf and Cmax, were determined using NCA 
implemented in PKNCA R package. The AUC was estimated using the trapezoidal rule 
(Gabrielsson and Weiner, 2012) and the Cmax corresponded with the highest 
concentration after IV infusion.  
 
3.3.2 Calculation of the modified standard normal deviates (mSND) 
 
The standard normal variate was calculated as follows: 
1. Compute the average of each exposure measure. 
μ ¡90¢ = AUCinf% + AUCinf + ⋯ + AUCinf0n  
 
μ9z = Cmax% + Cmax + ⋯ + Cmaxnn  
 
 
2. Compute the standard deviation of each exposure measure. 





σ9z =  ¥∑ (Cmax −  μ9z) 0$% n − 1  
 
3. Compute the modified standard normal deviate of each ith model.  
AUC SND =  (μ ¡90¢ − AUCinf)σ ¡90¢  
Cmax SND =  (μ9z − Cmax)σz  
 
4. Plot each of the models for a visual presentation of their deviates Figure 1. 
 
3.4 Selection of melphalan pharmacokinetic models  
 
A criterion of 0 – 3 mSND was used for model selection based on its ability to 
discriminate between models which were developed using different PK data and 
different model structure. The models within 0 -3 mSND were selected for repurposing, 
and subsequently used to generate a composite dataset for the development of the 









3.5 Development of the Composite Pharmacokinetic Model 
 
3.5.1 Non-Bayesian approach (FOCE-I) 
 
The composite dataset was used to develop a composite PK model. The composite 
dataset consisted of 100 virtual subjects. A two compartmental pharmacokinetic model 
was developed in NONMEM using First-order conditional estimation method (FOCE) 
with interaction. FOCE-I is an approximation of the maximum likelihood estimation 
method. The parameters estimated included CL, Q, V1 and V2. Inter-individual 
variability (IIV) or etas (η) associated with each of the parameters were estimated. The 
residual error variability or sigma (σ) was also estimated. The final model was evaluated 
using the goodness of fit (GoF) plots (dataset versus predictions, and residuals).  
 
3.5.2 Bayesian Method 
 
The Bayesian methodology was implemented in Stan using the NUTS MCMC 
algorithm to develop a two compartmental model. The model is expressed by equations 
(2a & b). Both weakly informative priors and informative priors of the fixed effects, 
CL, Q, V1, and V2 were examined during runs 1 and 2 respectively (Table 3). All other 









Table 3. Priors used for the Bayesian model development.     
Parameter Run 1 Run 2 
CL normal(0, 25) normal(27.7, 25) 
Q normal(0, 50) normal(19, 50) 
V1 normal(0, 10) normal(27.4, 10) 
V2 normal(0, 20) normal(15.7, 20) 
omega cauchy(0, 1) cauchy(0, 1) 
rho *lkj_corr(1)  lkj_corr(1) 
sigma cauchy(0, 1) cauchy(0, 1) 
 
 
The posterior distribution were expressed as: 
Log(φ) ~ multi_normal(log(φ), Omega) 
C ~ lognormal(log(y(CL, V1, Q, V2, t, D)), sigma) 
 
The conditions for each run were: number of chains = 4; burn-in samples = 500,  
post-burn-in samples = 1000;  number of iterations = 1500; and thinning number= 1. 
The convergence of the Markov chains were assessed by examining the traceplots 
for stationarity and mixing of the four chains. A straight horizontal fuzzy caterpillar, 
rather than a wiggly snake, is an indication of adequate mixing and hence convergence. 
Also the potential scale reduction statistics (Rhat) was examined. The Rhat compares 
the between and within variances of the chains (Brooks and Gelman, 1998). An Rhat of 
1 is an indication that all chains were in equilibrium and converged to a common 
distribution. Similar to the non-Bayesian approach, the composite dataset was compared 
















4.1 Description of published melphalan Pharmacokinetic models  
 
From the 6 published papers, 7 Pop PK models of melphalan were selected, and 
simulated (Figure 4). The 7 models represented melphalan PK in about 450 patients 
with multiple myeloma (MM) and malignancies, who were undergoing allogenic or 
autologous stem cell transplantation.  
 
 
Figure 4. Individual plots of simulated plasma concentration of melphalan: after 30 
minutes IV infusion of 140 mg/m2 of melphalan. M1: Nath et al. 2010a ;  M2: Nath et 
al. 2010b;  M3: Nath et al. 2007;  M4: Cho et al. 2018;  M5: Kuhne et al. 2007;  M6: 






Melphalan doses of 20 – 200 mg/m2 were administered in the original studies 
(Table 1). The data used to develop the original published models were from total 
melphalan plasma concentration, except M2 (Nath et al., 2010), which was developed 
using unbound concentration. Additionally, the original studies were conducted in adult 
patients except M3 (Nath et al., 2007), which was conducted in pediatric patients.  
The PK models were all described as two compartment models except M7 
(Mougenot et al., 2004), which was described as a one-compartmental model. At least, 
body weight or other measures of body weight was used as a covariate on a parameter 
in all the models used in this study. Other covariates found included creatinine clearance 
(CrCl), glomerular filtration rate (GFR), and hematocrit (HCT).  
 
4.2 The modified standard normal deviate (mSND) provided a criterion for 
discriminating published melphalan PK models. 
 
The modified standard normal deviate (mSND) used in this work provided an 
approach for discriminating the predictive performance of the published PK models. 
Models with exposure measures within a mSND of 0-3 were considered to be predictive 
of the 140 mg/m2 melphalan dose. Predictions of AUCinf and Cmax were all within 0-
3 SND, except M2 (Nath et al. 2010b) and M7 (Mougenot et al. 2004) which deviated 
by more than 3 units (Table 4 & Figure 5). This suggests three important things 







Table 4. Summary of the modified standard normal deviates (mSND) of 7 published 













M1 Nath et al. 
2010a 
9.1 2.2 9.4 2.9 
M2 Nath et al. 
2010b 
1.9 8.4 2.0 6.5 
M3 Nath et al. 
2007 
9.5 2.9 8.6 1.5 
M4 Cho et al. 2017 7.6 0.3 8.7 1.6 
M5 Kuhne et al. 
2007 
7.1 0.1 7.2 0.2 
M6 Mizuno et al. 
2018 
7.4 0.2 6.8 0.0 
M7 Mougenot et 
al. 2004 
4.1 2.4 2.6 5.1 
 
Firstly, it suggests that the data used to generate melphalan PK model is an 
important factor that can limit future predictions. Models based on unbound melphalan 
plasma concentration may not predict total plasma concentration adequately without an 
appropriate correction factor. For this reason, caution should be exercised when such 
models are repurposed to predict total plasma concentrations.   
Second, the structure of the Pop PK model is a source of variability in predictions. 
This is consistent with the higher mSND associated with the AUCinf  predicted by M7 
(Mougenot et al. 2004) presented in Figure 5. In the study design of M7 (Mougenot et 
al. 2004), unlike the other papers, melphalan was infused for more than 24 hours. M7 
design informed a one compartment model structure, and was inadequate to predict 
melphalan PK after short IV infusion like the others.  
Lastly, irrespective of the covariate used to explain between-subject variability in 
PK, majority of the models predicted AUCinf and Cmax within 3 mSND. This suggests 




and repurposed based on the covariates one can afford to measure. Alternatively, a 
composite model which combines all the eligible models can be developed and 












4.3 A 2-compartmental model adequately fit the melphalan composite data using 
FOCE-I. 
 
Using the non-Bayesian approach, a two compartmental model was developed 
from composite data generated from models M1, M3, M4, M5, and M6. The goodness 
of fit plots (GoF) showed adequate fit of the two compartmental model to the composite 
data (Figure 6). The model parameters were: clearance (CL), 27.7 L/hr; distributional 
clearance (Q), 27.4 L/hr; volume of central compartment (V1), 19 L; and volume of 
peripheral compartment (V2).  
 
 









Table 5. Pharmacokinetic parameters of the composite melphalan PK model using 
Bayesian HMC-NUTS estimation. 
Parameters based on weakly informative priors 
 
Mean SD 2.50% 97.50% n_eff Rhat 
CL 27.72 1.12 25.60 30.08 1836 1.00 
Q 25.57 2.44 20.89 30.56 14 1.08 
V1 19.08 1.03 17.13 21.17 1383 1.01 
V2 15.65 1.03 13.67 17.68 1124 1.01 
sigma 0.005 0.0001 0.005 0.005 1402 1.00 
omega[1] 0.41 0.03 0.36 0.47 1646 1.00 
omega[2] 0.87 0.13 0.64 1.12 3 1.65 
omega[3] 0.55 0.04 0.48 0.64 61 1.03 
omega[4] 0.62 0.05 0.53 0.73 32 1.04 
Parameters based on informative priors 
 
Mean SD 2.50% 97.50% n_eff Rhat 
CL 27.95 1.16 25.79 30.28 3821 1.00 
Q 25.94 2.45 21.10 30.82 16 1.07 
V1 19.42 1.08 17.36 21.63 2672 1.01 
V2 15.75 1.04 13.82 17.85 2852 1.01 
sigma 0.005 0.0001 0.005 0.005 3809 1.00 
omega[1] 0.41 0.03 0.36 0.47 4376 1.00 
omega[2] 0.87 0.13 0.65 1.11 3 1.65 
omega[3] 0.55 0.04 0.48 0.64 70 1.02 











4.4 A 2-compartmental model adequately fit the melphalan composite data using 
HMC – NUTS MCMC. 
 
Again, a two-compartmental model adequately fit the composite data when 
Hamiltonian Monte Carlo No-U-Turn-Sampler MCMC was used. This Bayesian 
methodology confirmed the non-Bayesian model developed using FOCE-I. Both 
informative and weakly-informative priors gave similar parameter estimates (Table 5). 
The traceplots and Rhat presented in the Appendix indicated successful convergence 
and adequate mixing of the chain.  
 
Table 6. Comparison of pharmacokinetic parameters of composite and reference 








CL (L/hr) 27.07 27.7 27.72 27.95 
Q (L/hr) 23.22 27.4 25.57 25.94 
V1 (L) 20.29 19 19.08 19.42 
V2 (L) 14.61 15.7 15.65 15.75 
Omega 1 
(%) 
- 40.6 41 41 
Omega 2 
(%) 
- 60.5 87 87 
Omega 3 
(%) 
- 55.3 55 55 
Omega 4 
(%) 
- 63.9 62 62 
Sigma 
(mg/L) 
0.036 0.0132 0.005 0.005 
FOCE-I, First-order conditional estimation with interaction; CL and Q are 
clearance parameters, V1 and V2 are volume of distribution parameters; Omega 1, 2, 







4.5 The Bayesian and non-Bayesian composite PK models of melphalan agree with 
the reference EVOMELA NDA model 
 
The reference model from the EVOMELA NDA packet was compared with the 
composite models developed using both Bayesian and non-Bayesian approaches. The 
parameter estimates (Table 6) and the model predictions (Figure 7) agree with those 
from the EVOMELA NDA packet. This confirmed that the modified standard normal 
deviate was able to select models with similar predictive performance, and those models 
could be combined into a composite model. Again, the agreement between the 
composite model and the reference suggests that literature data can be repurposed to 
develop composite PK models.   
 
Figure 7. Comparison of predictions from melphalan composite models and reference 
(EVOMELA NDA) model. The predictions of the composite and reference models are 
in agreement with each other. EVOMELA NDA; Reference model; FOCE-I First-order 
conditional estimation with interaction; NUTS:InPr, Bayesian composite model with 
informative prior; NUTS:WKInPr, Bayesian composite model with weakly informative 





4.6 Potential areas of application and summary of findings  
 
Model and parameter repurposing is common in quantitative clinical 
pharmacology, especially, in the development of complex quantitative systems 
pharmacology (QSP), and PBPK models. Usually, the base model and parameters are 
selected from literature and modified to provide evidence to support dosing and design 
of clinical trials. An example is the development of an integrated PBPK model of 
calcium homeostasis and bone biology (Peterson and Riggs, 2010), where three 
previously published models (Raposo et al., 2002, Lemaire et al., 2004, Bellido et al., 
2003) served as the foundation for the new one. The new model with calcium 
homeostasis component (Peterson and Riggs, 2010) was then used to perform 
simulations to support the adequacy of proposed dosing regimen in regulatory review 
of Natpara in hypothyroidism (Khurana et al., 2019).  
Similar to systems model, pharmacokinetic models of drugs may also be selected 
from literature and repurposed. Marketed drugs may have several PK models available 
in literature, which may be selected and repurposed to support the development of 
combination therapeutic products.  
In  this work, our approach offered two options for repurposing melphalan PK 
models (Figure 8). First, it offered us the option  of choosing any of M1, M3, M4, M5, 
M6 or the  reference model, depending on which covariates we are able to  afford. 
Second, it offered us a composite model which averaged   M1, M3, M4 , M5 and M6,  





Figure 8. Models to choose from for repurposing. M1: Nath et al. 2010a; M3: Nath et 
al. 2007;  M4: Cho et al. 2018;  M5: Kuhne et al. 2007;  M6: Mizuno et al. 2018;  BWT, 
body weight; FFM, free fat mass; HCT, hematocrit; CRCL, creatinine clearance; GFR, 






















The modified standard normal deviate provided an objective criterion for selection 
of melphalan models based on the prediction of exposure after a given dose. The 
approach showed that the PK data, unbound or total concentration, and model structure 
were sources of variability in the predictions of exposure measures.  
Additionally,  this approach guided the development of a composite Pop PK model 
which approximately averaged previous models. Bayesian, using informative and 
weakly informative priors, gave similar parameters and predictions like the non-
Bayesian approach. Predictions from the composted models agreed with predictions 
from reference model in EVOMELA Clinical Pharmacology NDA Review packet. This 
confirms the validity of the composite model and the approach used.   
It is hoped that further refinement of this approach will provide a more objective 
approach for selecting PK models for repurposing. In the future, the sample size for the 
SISA step can be optimized to mimic the proportion of subjects in the original studies. 










































6.3 Bayesian diagnostics: traceplots (left: informative priors; right weakly 
informative priors) 
      























6.4 Bayesian: Parameter distribution 
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